37 studies found for:    Open Studies | "Acromegaly"
Show Display Options
Rank Status Study
21 Recruiting Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Condition: Acromegaly
Intervention: Drug: Lanreotide PRF
22 Recruiting Acromegaly Combination Treatment Study
Condition: Acromegaly
Interventions: Drug: Pegvisomant;   Drug: Somatostatin Receptor Ligand (SRL)
23 Unknown  Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
Condition: Acromegaly
Intervention:
24 Unknown  Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Conditions: Acromegaly;   Type 2 Diabetes Mellitus
Interventions: Other: oral glucose tolerance test;   Other: Subcutaneous administration of recombinant human IGF-1
25 Recruiting Acromegaly Treatment Quality of Life Study
Condition: Acromegaly
Intervention:
26 Recruiting Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly;   Gigantism;   Familial Isolated Pituitary Adenoma;   FIPA;   Pituitary Adenoma Predisposition;   PAP
Intervention:
27 Unknown  Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs
Condition: Acromegaly
Intervention: Other: Oral Glucose Tolerance Test (OGTT)
28 Unknown  The Observational Study of Growth Hormone-secreting Pituitary Tumors
Conditions: Acromegaly;   Pituitary Tumor
Intervention:
29 Unknown  Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
Condition: Acromegaly
Interventions: Drug: Preoperative lanreotide treatment;   Procedure: Transsphenoidal surgery
30 Recruiting Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
Conditions: Acromegaly;   Excessive Growth Hormone Secretion;   Insulin Resistance
Intervention: Procedure: Transsphenoidal adenomectomy
31 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
32 Not yet recruiting Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
Condition: Acromegaly
Intervention:
33 Recruiting Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
Condition: Acromegaly
Intervention:
34 Recruiting Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
Condition: Acromegaly
Intervention: Drug: Sandostatin (Octreotide Acetate)
35 Unknown  Estrogen Treatment in Acromegalic Women
Condition: Acromegaly
Intervention: Drug: Alesse
36 Recruiting Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Condition: Pituitary Tumours
Intervention: Procedure: Gallium-68 DOTATOC PET
37 Unknown  Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
Condition: Pituitary Tumor
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-37) Next Page   
Indicates status has not been verified in more than two years